147 related articles for article (PubMed ID: 10540212)
1. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
Hart DN; Hill GR
Immunol Cell Biol; 1999 Oct; 77(5):451-9. PubMed ID: 10540212
[TBL] [Abstract][Full Text] [Related]
2. Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice.
Zeis M; Frenzke H; Schmitz N; Uharek L; Steinmann J
Bone Marrow Transplant; 2002 Feb; 29(3):213-21. PubMed ID: 11859393
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells in clinical trials for multiple myeloma.
Reichardt VL; Brossart P
Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.
Hájek R; Butch AW
Med Oncol; 2000 Feb; 17(1):2-15. PubMed ID: 10713654
[TBL] [Abstract][Full Text] [Related]
6. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
Rhee Fv
Clin Cancer Res; 2007 Mar; 13(5):1353-5. PubMed ID: 17332275
[No Abstract] [Full Text] [Related]
7. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
8. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.
Reichardt VL; Milazzo C; Brugger W; Einsele H; Kanz L; Brossart P
Haematologica; 2003 Oct; 88(10):1139-49. PubMed ID: 14555310
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in multiple myeloma immunotherapy.
Ruffini PA; Biragyn A; Kwak LW
Biomed Pharmacother; 2002 May; 56(3):129-32. PubMed ID: 12046683
[TBL] [Abstract][Full Text] [Related]
10. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.
Leitch HA; Connors JM
Curr Opin Investig Drugs; 2005 Jun; 6(6):597-604. PubMed ID: 15988911
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides.
Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM
Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631
[TBL] [Abstract][Full Text] [Related]
12. Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma.
Guardino AE; Rajapaksa R; Ong KH; Sheehan K; Levy R
Cytotherapy; 2006; 8(3):277-89. PubMed ID: 16793736
[TBL] [Abstract][Full Text] [Related]
13. DC in multiple myeloma immunotherapy.
Turtle CJ; Brown RD; Joshua DE; Hart DN
Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
[TBL] [Abstract][Full Text] [Related]
14. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
Yi Q; Desikan R; Barlogie B; Munshi N
Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
16. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
[TBL] [Abstract][Full Text] [Related]
17. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.
Bogen B; Ruffini PA; Corthay A; Fredriksen AB; Frøyland M; Lundin K; Røsjø E; Thompson K; Massaia M
Haematologica; 2006 Jul; 91(7):941-8. PubMed ID: 16818282
[TBL] [Abstract][Full Text] [Related]
18. Clinical applications of dendritic cell vaccines.
Morse MA; Lyerly HK
Curr Opin Mol Ther; 2000 Feb; 2(1):20-8. PubMed ID: 11249649
[TBL] [Abstract][Full Text] [Related]
19. The role of idiotype vaccines in the treatment of human B-cell malignancies.
Bendandi M
Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
[TBL] [Abstract][Full Text] [Related]
20. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.
Danylesko I; Beider K; Shimoni A; Nagler A
Clin Dev Immunol; 2012; 2012():753407. PubMed ID: 22649466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
